Celon Pharma (WAR:CLN) Total Liabilities: zł141.9 Mil (As of Mar. 2026)


WAR:CLN Celon Pharma SA WAR:CLN
48 GF Score
Price zł19.78
GF Value zł23.01
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Total Liabilities?

Celon Pharma WAR:CLN -0.10% 48 Total Liabilities is zł141.9 Mil as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 48/100 and a GF Value™ of zł23.01 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Celon Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was zł141.9 Mil.

Celon Pharma's quarterly Total Liabilities increased from Sep. 2025 (zł82.14 Mil) to Dec. 2025 (zł94.21 Mil) and increased from Dec. 2025 (zł94.21 Mil) to Mar. 2026 (zł141.95 Mil).

Celon Pharma's annual Total Liabilities declined from Dec. 2023 (zł123.75 Mil) to Dec. 2024 (zł98.59 Mil) and declined from Dec. 2024 (zł98.59 Mil) to Dec. 2025 (zł94.21 Mil).

Celon Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Total Liabilities Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.35 163.12 123.75 98.59 94.21

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.06 97.52 82.14 94.21 141.95
WAR:CLN
48GF Score
Celon Pharma SA WAR:CLN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Celon Pharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=63.269+(0+30.945
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=94.2

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=457.46-363.246
=94.2

Celon Pharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=107.879+(32.855+1.213
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=141.9

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=670.731-528.784
=141.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of zł141.9 Mil mean?
Celon Pharma (WAR:CLN) has a Total Liabilities of zł141.9 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Celon Pharma and its competitors.
Is Celon Pharma's Total Liabilities too high?
Celon Pharma's current Total Liabilities is zł141.9 Mil. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Total Liabilities compare to ZTS and UTHR?
Celon Pharma's Total Liabilities of zł141.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Celon Pharma and its competitors. Celon Pharma's current Total Liabilities is zł141.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.01, compared to a current price of zł19.78 — trading 14% below its estimated fair value. The current Total Liabilities is zł141.9 Mil. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Total Liabilities is zł141.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.78 is trading 14% below its estimated GF Value™ of zł23.01. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Total Liabilities: zł141.9 Mil
  • GF Value™: zł23.01 vs. price of zł19.78 (14% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for WAR:CLN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.78
Price
zł23.01
GF Value